Blood Advances

Conditioning intensity and probability of live birth after blood or marrow transplantation, a BMTSS report.  6:2471-2479. 2022

Molecular, clinical, and prognostic implications of PTPN11 mutations in acute myeloid leukemia.  6:1371-1380. 2022

Deferiprone vs deferoxamine for transfusional iron overload in SCD and other anemias: a randomized, open-label noninferiority study.  6:1243-1254. 2022

The ASH-ASPHO Choosing Wisely Campaign: 5 hematologic tests and treatments to question.  6:679-685. 2022

VpreB surrogate light chain expression in B-lineage ALL: A report from the Children's Oncology Group.  6:585-589. 2022

Restriction of HIV-1 infection in sickle cell trait.  5:4922-4934. 2021

Transcription factor MEF2D is required for the maintenance of MLL-rearranged acute myeloid leukemia.  5:4727-4740. 2021

Late-occurring venous thromboembolism in allogeneic blood or marrow transplant survivors: A BMTSS-HiGHS2 risk model.  5:4102-4111. 2021

Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma.  5:3748-3759. 2021

American Society of Hematology 2021 guidelines for sickle cell disease: Stem cell transplantation.  5:3668-3689. 2021

B-cell acute lymphoblastic leukemia in patients with germline RUNX1 mutations.  5:3199-3202. 2021

Phase 3 randomized trial of chemotherapy with or without oblimersen in older AML patients: CALGB 10201 (Alliance).  5:2775-2787. 2021

Gene expression signature predicts relapse in adult patients with cytogenetically normal acute myeloid leukemia.  5:1474-1482. 2021

Daratumumab plus RVd for newly diagnosed multiple myeloma: Final analysis of the safety run-in cohort of GRIFFIN.  5:1092-1096. 2021

Comparison of CALGB 10403 (Alliance) and COG AALL0232 toxicity results in young adults with acute lymphoblastic leukemia.  5:504-512. 2021

Acute erythroid leukemia is enriched in NUP98 fusions: A report from the Children's Oncology Group.  4:6000-6008. 2020

Elevated plasma levels of syndecan-1 and soluble thrombomodulin predict adverse outcomes in thrombotic thrombocytopenic purpura.  4:5378-5388. 2020

Systems-based hematology: Highlighting successes and next steps.  4:4574-4583. 2020

Building access to care in adult sickle cell disease: Defining models of care, essential components, and economic aspects.  4:3804-3813. 2020

American society of hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adults.  4:3528-3549. 2020

Chromosome 1 abnormalities and survival of patients with multiple myeloma in the era of novel agents.  4:2245-2253. 2020

Clinical outcomes of older patients with AML receiving hypomethylating agents: A large population-based study in the United States.  4:2192-2201. 2020

Myelodysplastic syndrome unrelated to lentiviral vector in a patient treated with gene therapy for sickle cell disease.  4:2058-2063. 2020

A phase 2 study of ATRA, arsenic trioxide, and gemtuzumab ozogamicin in patients with high-risk APL (SWOG 0535).  4:1683-1689. 2020

Patterns of care and clinical outcomes with cytarabine-anthracycline induction chemotherapy for AML patients in the United States.  4:1615-1623. 2020

Thrombotic, inflammatory, and HIF-regulated genes and thrombosis risk in polycythemia vera and essential thrombocythemia.  4:1115-1130. 2020

Clinical and functional significance of circular RNAs in cytogenetically normal AML.  4:239-251. 2020

Outcomes of patients with limited-stage aggressive large B-cell lymphoma with high-risk cytogenetics.  4:253-262. 2020

Sex differences in the trajectory of glomerular filtration rate in pediatric and murine sickle cell anemia.  4:263-265. 2020

Longitudinal assessments of plasma ADAMTS13 biomarkers predict recurrence of immune thrombotic thrombocytopenic purpura.  3:4177-4186. 2019

American Society of Hematology 2019 guidelines for sickle cell disease: Cardiopulmonary and kidney disease.  3:3867-3897. 2019

End points for sickle cell disease clinical trials: Renal and cardiopulmonary, cure, and low-resource settings.  3:4002-4020. 2019

Hyperfiltration predicts long-term renal outcomes in humanized sickle cell mice.  3:1460-1475. 2019

Phase 1b study of the MDM2 inhibitor AMG 232 with or without trametinib in relapsed/refractory acute myeloid leukemia.  3:1939-1949. 2019

Defining the epigenetic status of blood cells using a cyanine-based fluorescent probe for PRMT1.  2:2829-2836. 2018

The impact of phlebotomy and hydroxyurea on survival and risk of thrombosis among older patients with polycythemia vera.  2:2681-2690. 2018

Double-blind, randomized, multicenter phase 2 study of SC411 in children with sickle cell disease (SCOT trial).  2:1969-1979. 2018

Platelet transfusions improve hemostasis and survival in a substudy of the prospective, randomized PROPPR trial.  2:1696-1704. 2018

Ten-year outcome of patients with acute myeloid leukemia not treated with allogeneic transplantation in first complete remission.  2:1645-1650. 2018

T-cell prolymphocytic leukemia in an adolescent with ataxiatelangiectasia: Novel approach with a JAK3 inhibitor (tofacitinib).  1:2724-2728. 2017

Allogeneic bone marrow transplant in the absence of cytoreductive conditioning rescues mice with β-thalassemia major.  1:2421-2432. 2017

Mesenchymal stem cells expressing osteoprotegerin variants inhibit osteolysis in a murine model of multiple myeloma.  1:2375-2385. 2017

Recent trends in multiple myeloma incidence and survival by age, race, and ethnicity in the United States.  1:282-287. 2017

Therapeutic efficacy of the platelet glycoprotein Ib antagonist anfibatide in murine models of thrombotic thrombocytopenic purpura..  1:75-83. 2016